Sutro Biopharma

Celgene collaborates with Sutro Biopharma, inks option to acquire

Friday, October 24, 2014

Sutro Biopharma, located in South San Francisco, has entered into a strategic collaboration and option agreement with Celgene to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapeutics.

[Read More]

Sutro Biopharma, EMD Serono partner on antibody drug conjugates

Thursday, September 18, 2014

Sutro Biopharma, a California-based biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and EMD Serono, the biopharmaceutical division of Merck, have inked a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

[Read More]